Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Gao X, Ji K, Jia Y, Shan F, Chen Y, Xu N, Jia Z, Liu T, Yang N, Zhong H, Li C, Guo Z, Fan Q, Lin X, Zhang Y, Ren H, Yang H, Yao Z, Liu W, Wang Z, Li B, Xia M, Shen L, Li Z, Ji J. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature Medicine 2024, 30: 1943-1951. PMID: 38778212, DOI: 10.1038/s41591-024-03007-5.Peer-Reviewed Original ResearchGastroesophageal junction adenocarcinomaRecommended phase 2 dosePD-L1 CPSPhase 2 doseProgression-free survivalDuration of responsePD-L1Overall survivalGastroesophageal junctionMedian OSPD-1Primary endpointHuman epidermal growth factor receptor 2-negativeAnti-programmed cell death protein 1Cytotoxic T-lymphocyte antigen 4Cell death 1 ligand 1Programmed cell death 1 ligand 1Anti-PD-1 therapyMedian duration of responsePhase 1bTreatment-related grade 3Cell death protein 1T-lymphocyte antigen-4Antibodies targeting PD-1Response rateEfficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial
Guo X, Lou W, Xu Y, Zhuang R, Yao L, Wu J, Fu D, Zhang J, Liu J, Rong Y, Jin D, Wu W, Xu X, Ji Y, Wu L, Lv M, Yao X, Liu X, Wang D, Kuang T, Liu L, Wang W, Liu T, Zhou Y. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Oncology Letters 2024, 27: 161. PMID: 38449794, PMCID: PMC10915801, DOI: 10.3892/ol.2024.14293.Peer-Reviewed Original ResearchProgression-free survivalAdvanced pancreatic cancerC-reactive proteinPancreatic cancerAS regimenNab-paclitaxelAdvanced PCPrimary endpointGene mutationsEfficacy of nab-paclitaxelPatients treated with GSSafety of nab-paclitaxelMedian progression-free survivalMedian follow-up timePhase II randomized trialC-reactive protein levelsHigh C-reactive proteinImproved overall survivalSubsets of patientsFollow-up timeCost-effective treatment regimenOS benefitData cutoffOpen-labelOverall survivalFruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study.
Xu R, Wang F, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Shu Y, Zhao F, Cheng Y, Ye F, Gu K, Zhang T, Pan H, Zhong H, Su W. Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study. Journal Of Clinical Oncology 2024, 42: 438780-438780. DOI: 10.1200/jco.2024.42.36_suppl.438780.Peer-Reviewed Original ResearchPhase 3 studyAntitumor therapyMedian OSDouble-blindPrimary endpointInhibitor of VEGFR-1Dose of study drugSecond-line treatment optionDual primary endpointsPlacebo (PBO)-controlledFirst-line chemotherapyGastroesophageal junction adenocarcinomaMetastatic colorectal cancerSecond-line therapyLymph node metastasisTreatment of paclitaxelStatistical significanceCox proportional hazards modelsPost hoc analysisOral inhibitorJunction adenocarcinomaEligible ptsPlacebo-controlledStudy drugStatistically significant improvement